Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III TrialPaul E. Goss, Lois E. Shepherd, James N. Ingle et al.|Journal of Clinical Oncology|2013Cited by 261
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trialPaul E. Goss, Lois E. Shepherd, Dawn L. Hershman et al.|The Lancet Oncology|2014Cited by 53
Abstract P1-07-06: Adjunctive statistical standardization of quantitated adjuvant HER2 and very low statistically standardized HER2 in CCTG MA.27Judith-Anne Chapman, Karen J. Taylor, Shakeel Virk et al.|Clinical Cancer Research|2025Cited by 0